Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)

NCT02493049 | Completed Phase 2

• 1 other identifier: DOM-RRMS-01
• Study Type: interventional
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

The first major objective of this pilot trial is to demonstrate that it is possible to study myelin repair in relapsing-remitting multiple sclerosis (RRMS) patients with enhancing lesions on MRI by using advanced imaging techniques. To demonstrate that this is possible the investigators will recruit 24 RRMS patients who are being treated with standard disease modifying therapy (DMT) and have new lesions identified on clinically indicated brain MRI scans and measure myelin repair at 16 and 32 weeks using MRI measures of myelin repair. The second major objective is to determine how much repair occurs in participants treated with domperidone compared with those who are not treated. This will allow us to design larger trials to confirm that domperidone improves repair. The study will also confirm the safety and tolerability of domperidone in RRMS, determine circulating prolactin levels during dosing with domperidone 10mg three times daily in people with RRMS, and explore the impact of other clinical factors (such as age) on lesion repair. In addition, blood will be collected to test for metabolomics and the investigators will bank blood for future study of biomarkers that can help the investigators better understand MS. Metabolomics is an experimental test where changes in the pattern of the chemicals in blood cells are compared at different time points (during and after inflammation). There will be random changes but changes that are common in most study participants may help identify chemicals that signal stages in injury or repair. The investigators will also compare the pattern of change in those with the best repair to those with the worst repair. This may help identify a chemical that is associated with better or worse repair and help develop new treatment strategies. There are currently no blood tests that help in the diagnosis of MS, help determine which drug a person will respond to, or help determine a person's expected MS outcome. Any such tests would be considered biomarkers.

Conditions

Multiple Sclerosis, Relapsing-Remitting

Keywords

Multiple Sclerosis; Domperidone; Relapsing-Remitting MS; Demyelinating disease; Remyelination

Outcome Measures

Primary Outcomes (1)

• Measures of repair within enhancing T1 MRI lesions

  Texture analysis, Diffusion Tensor Imaging (DTI) and Magnetization Transfer Imaging (MTI) will be used. This is a pilot study so the investigators are measuring repair at 2 time points and with 3 imaging methods to aid in the design of future studies.

  up to 32 weeks

Secondary Outcomes (2)

• Number and type of adverse events over the 16 week treatment period.

  at 6 and 16 weeks

• Serum Prolactin Levels at both 6 and 16 weeks

  at 6 and 16 weeks

Study Arms (2)

Domperidone

EXPERIMENTAL

Add on oral Domperidone 10 mg, three times daily. Target dose:30mg daily. Duration: 16 weeks

Drug: Domperidone

No add on treatment

NO INTERVENTION

No add on treatment. Control group

Interventions

Domperidone DRUG

Addition of Domperidone to current Disease Modifying Therapy.

Also known as: domperidone maleate

Domperidone

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participants must be between age 18 and 60 years.
• Sexually active men and women of child-bearing potential, defined as those who are not postmenopausal (24 consecutive months) or permanently sterilised, must agree to use adequate contraception. Adequate contraception is defined as methods of birth control which result in a low failure rate \[i.e. less than 1% per year\] when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), barrier contraceptives, sexual abstinence or vasectomised partner. Adequate contraception is required during domperidone treatment and for one month after stopping treatment.
• Participants must have MS defined according to the McDonald criteria (Polman et al. 2011).
• Participants must have RRMS according to Lublin et al. (2014).
• Participants must have been treated with a stable approved dose of glatiramer acetate, interferon-beta, fingolimod, dimethyl fumarate, or teriflunomide for at least 6 months.
• Participants must be scheduled to have a clinically indicated brain MRI to monitor DMT effectiveness.
• Participants must have at least one gadolinium enhancing lesion on their DMT monitoring MRI (screening MRI).
• Participants must report at least 80% adherence to their current DMT and have had no treatment discontinuation for one week or longer within the prior 6 months.
• Participants must be patients of the Calgary MS Clinic.
• Participants must provide written informed consent

You may not qualify if:

• Participants who are pregnant or breastfeeding
• Participants in whom it is expected that their current DMT will be discontinued within 16 weeks. Indicators of likely discontinuation will include poor DMT tolerance, a wish by the participant to discontinue the DMT, or a history of poor clinical response to the current DMT (such as a relapse within the previous year while on the current DMT)
• Participants who have a long QT interval, defined as corrected QT interval of more than 470 msec in men and more than 450 msec in women, on screening ECG.
• Participants with known long-QT syndrome or known cardiac arrhythmia.
• Participants who currently or previously have been treated with natalizumab.
• Participants who are currently treated with domperidone or have taken it within the previous 3 months.
• Participants who are taking drugs which prolong QT intervals or who are treated with drugs that inhibit cytochrome P450 3A4.
• Participants who are concurrently treated with drugs that may increase serum prolactin levels.
• Participants who have a prolactinoma
• Participants who use systemic corticosteroids within the 8 weeks prior to the screening MRI or who use concurrent immunosuppressive medications including systemic corticosteroids.
• Participants who have a history of breast cancer or breast carcinoma in situ or who have clinically significant depression, renal, hepatic, cardiovascular, respiratory, metabolic, ophthalmologic, cerebrovascular, or other serious physical disease.
• Participants in whom gastrointestinal stimulation might be dangerous, i.e. gastrointestinal hemorrhage or mechanical obstruction or perforation
• Participants who have a known allergy or other intolerability to domperidone.
• Participants with serum potassium, sodium, magnesium or calcium levels outside the normal range, serum creatinine \> 6 mg/100 ml or \> 0.6 mmol/l), or who have any other condition or situation that in the opinion of the investigator would either put the patient at risk of worsening health if enrolled in the trial or would prevent completion of the trial.
• Participants who are concurrently participating in any therapeutic clinical trial.

Sponsors & Collaborators

• University of Calgary: lead
• Alberta Innovates Health Solutions: collaborator

Study Sites (1)

Calgary MS Clinic at Foothills Medical Centre

Calgary, Alberta, T2N 2T9, Canada

Location

Related Publications (21)

• Alonso-Ortiz E, Levesque IR, Pike GB. MRI-based myelin water imaging: A technical review. Magn Reson Med. 2015 Jan;73(1):70-81. doi: 10.1002/mrm.25198. Epub 2014 Mar 6.

  PMID: 24604728 BACKGROUND

• Bagnato F, Jeffries N, Richert ND, Stone RD, Ohayon JM, McFarland HF, Frank JA. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain. 2003 Aug;126(Pt 8):1782-9. doi: 10.1093/brain/awg182. Epub 2003 Jun 23.

  PMID: 12821527 BACKGROUND

• Barkhof F, Bruck W, De Groot CJ, Bergers E, Hulshof S, Geurts J, Polman CH, van der Valk P. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol. 2003 Aug;60(8):1073-81. doi: 10.1001/archneur.60.8.1073.

  PMID: 12925362 BACKGROUND

• Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol. 2009 May;5(5):256-66. doi: 10.1038/nrneurol.2009.41.

  PMID: 19488083 BACKGROUND

• Bernini GP, Lucarini AR, Franchi F, Salvetti A. Humoral effects of metoclopramide and domperidone in normal subjects and in hypertensive patients. J Endocrinol Invest. 1988 Nov;11(10):711-6. doi: 10.1007/BF03350925.

  PMID: 2852692 BACKGROUND

• Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 Dec 9;61(11):1528-32. doi: 10.1212/01.wnl.0000096175.39831.21.

  PMID: 14663037 BACKGROUND

• Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G; Eurpoean/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology. 2001 Aug 28;57(4):731-3. doi: 10.1212/wnl.57.4.731.

  PMID: 11524494 BACKGROUND

• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 Jan 29;338(5):278-85. doi: 10.1056/NEJM199801293380502.

  PMID: 9445407 BACKGROUND

• Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000 Dec;48(6):893-901.

  PMID: 11117546 BACKGROUND

• Metz LM, Zhang Y, Yeung M, Patry DG, Bell RB, Stoian CA, Yong VW, Patten SB, Duquette P, Antel JP, Mitchell JR. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol. 2004 May;55(5):756. doi: 10.1002/ana.20111. No abstract available.

  PMID: 15122721 BACKGROUND

• Sloka S, Metz LM, Hader W, Starreveld Y, Yong VW. Reduction of microglial activity in a model of multiple sclerosis by dipyridamole. J Neuroinflammation. 2013 Jul 18;10:89. doi: 10.1186/1742-2094-10-89.

  PMID: 23866809 BACKGROUND

• Chandran S, Hunt D, Joannides A, Zhao C, Compston A, Franklin RJ. Myelin repair: the role of stem and precursor cells in multiple sclerosis. Philos Trans R Soc Lond B Biol Sci. 2008 Jan 12;363(1489):171-83. doi: 10.1098/rstb.2006.2019.

  PMID: 17282989 BACKGROUND

• Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci. 2002 Sep;3(9):705-14. doi: 10.1038/nrn917.

  PMID: 12209119 BACKGROUND

• Zhao C, Fancy SP, Kotter MR, Li WW, Franklin RJ. Mechanisms of CNS remyelination--the key to therapeutic advances. J Neurol Sci. 2005 Jun 15;233(1-2):87-91. doi: 10.1016/j.jns.2005.03.008.

  PMID: 15949498 BACKGROUND

• Gregg C, Shikar V, Larsen P, Mak G, Chojnacki A, Yong VW, Weiss S. White matter plasticity and enhanced remyelination in the maternal CNS. J Neurosci. 2007 Feb 21;27(8):1812-23. doi: 10.1523/JNEUROSCI.4441-06.2007.

  PMID: 17314279 BACKGROUND

• Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y, Li XM. Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatry. 2008 Jul;13(7):697-708. doi: 10.1038/sj.mp.4002064. Epub 2007 Aug 7.

  PMID: 17684494 BACKGROUND

• Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic. CNS Drugs. 2013 Jul;27(7):493-503. doi: 10.1007/s40263-013-0068-8.

  PMID: 23681979 BACKGROUND

• Nerozzi D, Magnani A, Dastoli C, Ferri E, Capesciotti G, Antonozzi I, Frajese G, Meltzer HY. Prolactin responses to domperidone in chronic schizophrenia. Psychiatry Res. 1992 May;42(2):159-69. doi: 10.1016/0165-1781(92)90079-i.

  PMID: 1631251 BACKGROUND

• Knoppert DC, Page A, Warren J, Seabrook JA, Carr M, Angelini M, Killick D, Dasilva OP. The effect of two different domperidone doses on maternal milk production. J Hum Lact. 2013 Feb;29(1):38-44. doi: 10.1177/0890334412438961. Epub 2012 May 3.

  PMID: 22554679 BACKGROUND

• Mallik S, Samson RS, Wheeler-Kingshott CA, Miller DH. Imaging outcomes for trials of remyelination in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1396-404. doi: 10.1136/jnnp-2014-307650. Epub 2014 Apr 25.

  PMID: 24769473 BACKGROUND

• Zhang Y, Liu WQ, Hosseinpour Z, Pike GB, Cerchiaro G, Greenfield J, Yong VW, Metz LM. Feasibility study to assess lesion repair in relapsing-remitting multiple sclerosis: A randomized controlled pilot clinical trial of domperidone add-on treatment. Mult Scler Relat Disord. 2024 May;85:105525. doi: 10.1016/j.msard.2024.105525. Epub 2024 Feb 27.

  PMID: 38461731 DERIVED

MeSH Terms

Conditions

Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Demyelinating Diseases

Interventions

Domperidone

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Piperidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Luanne M Metz, MD

  University of Calgary

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Neurologist, Professor of Clinical Neurosciences, MD, FRCPC

Study Record Dates

• First Submitted: July 2, 2015
• First Posted: July 9, 2015
• Study Start: August 1, 2015
• Primary Completion: February 1, 2019
• Study Completion: February 1, 2019
• Last Updated: October 8, 2019

Record last verified: 2019-10

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)